Do you know if the drugs you are prescribed and are taking are actually delivering value? Who has your best interests front and center and you trust to make a determination and guide the clinical decision-making process on what therapy is indicated for the disease in you? If you were leaning on the FDA, recent news and events might give you pause. Recently conditionally approved Aduhelm an Alzheimer treatment by Biogen is controversial and pricey. Medicare premiums at all time high in part from the impact of Aduhelm. So what about the information and data available, the science? Drug pricing is outstripping our ability to pay, and a large portion of these escalating costs is linked to specialty drugs that can account for as much as 50% of costs while only treating a small percentage of patients.